Skip to content

N-acetyl-cysteine (NAC) and Kidney Graft Function

Preventive Administration of N-acetyl-cysteine (NAC) in Organ Donor: Effects on Kidney Graft Function

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00998972
Enrollment
236
Registered
2009-10-21
Start date
2006-09-30
Completion date
2011-06-30
Last updated
2011-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Death, Chronic Renal Insufficiency

Keywords

kidney graft,, delayed graft function, N-acetylcysteine

Brief summary

The goal of this study is to evaluate the effect of N-acetyl-cysteine (NAC) administration in organ donors on the kidney graft function of recipients.

Detailed description

Ischemia-reperfusion is a major contributing factor for delayed renal function after transplantation. It has been shown that the administration of an antioxidant, i.e. NAC, in patients with chronic renal insufficiency may prevent radio contrast-induced nephropathy. Due to its antioxidant effects, organ donor pretreatment with NAC has demonstrated to improve renal graft function in two experimental studies. Study objectives: to compare the incidence of delayed graft renal function between two groups of patients, i.e., those receiving the graft from organ donors pretreated with NAC and a group control. The primary endpoint was the number of delayed graft function defined as the requirement of at least one sequence of dialysis during the first seven days following transplantation. Secondary endpoints: evolution of creatininemia, azotemia at day 1, 7, 14 and ,30 after surgery; acute and delayed transplant rejection; intrahospital mortality. Patients inclusion: all organ donors and recipients were eligible Exclusion criteria: for organ donors were preexistent chronic renal insufficiency and contra-indications for kidney procurement; for recipient were transplantation outside our hospital The donors were randomized in a single-blind fashion into two groups : the control group and the group receiving 600 mg IV of NAC 1 hour before and 600 mg IV 2 hours after cerebral arteriography required to diagnose brain death. Sample size has been calculated delayed graft function by 50% leading to include 118 recipients in each group. Follow up: one year after transplantation. Study beginning in september 2006. Length of inclusion during 36 months.

Interventions

DRUGN-acetylcysteine

600 mg intravenous before and 2 hours after cerebral arteriography

Sponsors

Institut d'Anesthesiologie des Alpes Maritimes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* all recipient for kidney graft in our hospital

Exclusion criteria

* transplantation out side our hospital * refusal from the patient

Design outcomes

Primary

MeasureTime frame
Incidence of delayed graft function1 year

Secondary

MeasureTime frame
Evolution of creatininemia and azotemia during the first month after transplantation30 days
Intrahospital mortality30 days
Acute and delayed graft rejection30 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026